Veradermics, Inc
MANE · XNYSCIK 1827635fmd_1088YDX3KC9W7G76DFH0NH64SVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2024 to Sep 30, 2026, 8 periods
| Line item | FY2024 | FY2025 |
|---|---|---|
| Research and development | 23 | 62 |
| Total operating expenses | 27 | 72 |
| Operating income | (27) | (72) |
| Interest expense | 1 | 0 |
| Interest and investment income | 0 | 2 |
| Other non-operating income (expense) | 0 | 2 |
| Income before taxes | (26) | (70) |
| Income tax expense | 0 | 0 |
| Net income from continuing operations | (26) | (70) |
| Net income | (26) | (70) |
| Net income to common shareholders | (27) | (83) |